Full Press Release Details
Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease.
IRD
Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
Key Takeaway: Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+140%
120-day peak, hindsight
Typical move
6.3%
average across 11 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
APX3330
Phase 2 · Diabetic Retinopathy